• Signed written informed consent approved by the Ethical Review Board (IRB).

• Age ≥ 18 to \< 76 years.

• Histologically confirmed unilateral adenocarcinoma of the breast where neoadjuvant chemotherapy followed by definitive surgery is planned.

• Node positive disease (N1-3) or if clinically N0 Tumor size \>20 mm. When deciding T-stage the following hierarchy applies,

∙ MRI

‣ Ultrasound

‣ Mammography

‣ Clinical examination

• ER negative tumor defined by at least one the following:

∙ ER \< 1% cells positive by immunohistochemistry (IHC) or ER ≤ 10% cells positive by IHC and basal-like subtype using gene expression analysis

‣ ER \< 10% cells positive by IHC and PgR \< 10% cells positive by IHC

• HER2-normal tumor defined according to applicable national guidelines

• Consent for germline mutation screening for BRCA1, BRCA2 and other inherited breast cancer associated genes.

• WHO performance status 0 or 1.

• Negative pregnancy test in women of childbearing potential (premenopausal or \<12 months of amenorrhea post-menopause and who have not undergone surgical sterilization).

⁃ Willingness of female patients of childbearing potential, male patients, and their sexual partners to use an effective means of contraception during the treatment period and at least 6 months thereafter.

⁃ Willingness by the patient to undergo treatment and study related procedures according to the protocol.